+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 4
Age: 18Years - 60Years
All Genders
ID07191873

Evaluating Tirzepatide Compared to Placebo for Treating Idiopathic Intracranial Hypertension in Adults

Led by Duke University · Updated on 2026-09-15

60

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effect of tirzepatide on people with Idiopathic Intracranial Hypertension IIH, a condition characterized by increased pressure inside the skull. This randomized, double-blind, placebo-controlled Phase IV trial will compare changes in intracranial pressure over 12 months between participants receiving tirzepatide and those receiving a placebo. The study aims to better understand the treatments impact on this condition using detailed statistical methods. Participants are randomly assigned to receive either tirzepatide or a placebo weekly for one year. The dose increases gradually from 2.5 mg in the first month to 15 mg from month seven through twelve. Both groups follow the same dosing schedule. The study includes two treatment arms and uses a quadruple masking approach to maintain objectivity. During the year-long study, participants will have their intracranial pressure measured from enrollment through the end of treatment. Additional assessments include imaging tests to evaluate retinal nerve fiber layer thickness and changes in papilledema and perimetric mean deviation. Researchers will monitor participants for safety and treatment adherence. The total participation duration covers the full 12 months of treatment, with regular evaluations throughout this period.

CONDITIONS

Brief Title

Tirzepatide in Idiopathic Intracranial Hypertension Trial

Research Team

A

Alexa N Bramall, MD

B

Beth Perry, RN

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here